tgn-1412
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01885624)
Timeline
Indications
Mechanism of action
CD28 agonist
CD28 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109250 ↗
Also known as
- cd28-supermab
- monoclonal antibody tgn1412
- tab08
- tab08
- tgn1412
- tgn 1412
- tgn-1412
- tgn-1412
- tgn-1412 monoclonal antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03006029 | Phase 1 | Feb 8, 2017 | Theramab LLC |
| NCT02796053 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Theramab LLC |
| NCT02711813 | Phase 2 | Mar 1, 2016 | Theramab LLC |
| NCT01990157 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2013 | Theramab LLC |
| NCT01885624 | Phase 1 | Nov 1, 2011 | Clinical Emergency Hospital of Yaroslavl, Theramab LLC |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Theramab LLC | For profit | 5 | 5 | 2 | 2011 |
| Clinical Emergency Hospital of Yaroslavl | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1